N-terminal brain natriuretic peptide predicted cardiovascular events stronger than high-sensitivity C-reactive protein in hypertension: a LIFE substudy
- PMID: 16877955
- DOI: 10.1097/01.hjh.0000239288.10013.04
N-terminal brain natriuretic peptide predicted cardiovascular events stronger than high-sensitivity C-reactive protein in hypertension: a LIFE substudy
Abstract
Background: N-terminal pro-brain natriuretic peptide (Nt-proBNP) and high-sensitivity C-reactive protein (hsCRP) are cardiovascular risk markers in various populations, but are not well examined in hypertension. Therefore, we wanted to investigate whether high Nt-proBNP or hsCRP predicted the composite endpoint of cardiovascular death, non-fatal stroke or non-fatal myocardial infarction independently of traditional cardiovascular risk factors and the urine albumin: creatinine ratio (UACR), which is a well established cardiovascular risk factor in hypertension.
Methods: In 945 hypertensive patients from the LIFE study with electrocardiographic left ventricular (LV) hypertrophy, we measured traditional cardiovascular risk factors including electrocardiography, morning UACR, hsCRP by immunoturbidimetry assay and Nt-proBNP by immunoassay after 2 weeks of placebo treatment. During 55 months' follow-up 80 patients suffered a composite endpoint.
Results: HsCRP as well as Nt-proBNP above the median values of 3.0 mg/l and 170 pg/ml, respectively, was associated with a higher incidence of composite endpoint (13.1 versus 3.8%, P < 0.01, and 11.5 versus 5.4%, P < 0.01). In Cox regression analyses, standardized log(hsCRP)/SD predicted a composite endpoint [hazard ratio (HR) 1.3 per SD = 0.47 log(mg/l), P < 0.05] after adjustment for traditional cardiovascular risk factors, but not after further adjustment for UACR. Standardized log(Nt-proBNP)/SD predicted a composite endpoint after adjustment for traditional cardiovascular risk factors [HR 1.9 per SD = 0.49 log(pg/ml), P < 0.05] as well as after further adjustment for UACR [HR 1.5 per SD = 0.49 log(pg/ml), P < 0.01]. Log(Nt-proBNP) added significantly to the Cox regression models using traditional cardiovascular risk factors with and without UACR (both P < 0.001).
Conclusion: Nt-proBNP predicted a composite endpoint after adjustment for traditional risk factors, UACR and a history of diabetes or cardiovascular disease and added significantly to the prediction of composite endpoint, whereas hsCRP did not.
Similar articles
-
Cardiovascular risk prediction by N-terminal pro brain natriuretic peptide and high sensitivity C-reactive protein is affected by age and sex.J Hypertens. 2008 Jan;26(1):26-34. doi: 10.1097/HJH.0b013e3282f18301. J Hypertens. 2008. PMID: 18090537
-
N-terminal pro-brain natriuretic peptide, but not high sensitivity C-reactive protein, improves cardiovascular risk prediction in the general population.Eur Heart J. 2007 Jun;28(11):1374-81. doi: 10.1093/eurheartj/ehl448. Epub 2007 Jan 22. Eur Heart J. 2007. PMID: 17242007
-
Reductions in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: the LIFE study.J Hypertens. 2006 Apr;24(4):775-81. doi: 10.1097/01.hjh.0000217862.50735.dc. J Hypertens. 2006. PMID: 16531808
-
Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.Curr Med Res Opin. 2007 Feb;23(2):443-57. doi: 10.1185/030079906X167435. Curr Med Res Opin. 2007. PMID: 17288698 Review.
-
Rationale for testing the cardiovascular risk for patients with COX-2 inhibitors on the basis of biomarker NT-proBNP.Clin Lab. 2005;51(1-2):63-83. Clin Lab. 2005. PMID: 15719708 Review. English, German.
Cited by
-
Natriuretic Peptides and Assessment of Cardiovascular Disease Risk in Asymptomatic Persons.Curr Cardiovasc Risk Rep. 2010 Mar;4(2):120-127. doi: 10.1007/s12170-010-0078-8. Epub 2010 Feb 17. Curr Cardiovasc Risk Rep. 2010. PMID: 20672100 Free PMC article.
-
The association between left ventricular mass index and serum sirtuin 3 level in patients with hypertension.Cardiovasc Endocrinol Metab. 2020 Aug 27;10(2):99-105. doi: 10.1097/XCE.0000000000000231. eCollection 2021 Jun. Cardiovasc Endocrinol Metab. 2020. PMID: 34113795 Free PMC article.
-
What Is the Current Best Drug Treatment for Hypertensive Heart Failure With Preserved Ejection Fraction? Review of the Totality of Evidence.Am J Hypertens. 2024 Jan 1;37(1):1-14. doi: 10.1093/ajh/hpad073. Am J Hypertens. 2024. PMID: 37551929 Free PMC article.
-
Combination of high-sensitivity troponin I and N-terminal pro-B-type natriuretic peptide predicts future hospital admission for heart failure in high-risk hypertensive patients with preserved left ventricular ejection fraction.Heart Vessels. 2017 Jul;32(7):880-892. doi: 10.1007/s00380-017-0948-9. Epub 2017 Feb 2. Heart Vessels. 2017. PMID: 28154958
-
Natriuretic Peptide testing in primary care.Curr Cardiol Rev. 2008 Nov;4(4):300-8. doi: 10.2174/157340308786349499. Curr Cardiol Rev. 2008. PMID: 20066138 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials